Pembrolizumab in HNSCC With Residual Disease After Radiation

Summary

This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy). Patients must be diagnosed with residual disease within 24 weeks of completion of radiation therapy. Residual disease must be biopsy proven before the patient can consent to the trial, and can be either from lymph nodes in the neck, or from the primary tumor site. Prior to beginning study therapy patients are evaluated by an ENT to determine if they have disease amenable to surgical resection. Both resectable and unresectable patients will be eligible for participation in the study.

Timeline

Start

2016-09-08

Primary completion

2020-02

Completion

2020-03

Outcome

Outcome not reported

Stopped (Enrollment): “Low enrollment”

Drugs

Indications